T he last 12 months have been a watershed for major developments in stem cell intellectual property (IP). After reexamination proceedings held in March 2007, the US Patent and Trademark Office (USPTO; Washington, DC) issued a preliminary rejection of three of James Thomson's foundational embryonic stem (ES) cell patents (commonly known as '780, '806 and '913; Table 1) 1 . The reexamination, initiated by consumer-rights organizations, sprung from concerns over the patents' broad reach (the patents claim both the method to make human ES cell lines and the lines themselves, also known as the 'composition of matter') and the licensing strategies taken by Thomson's sponsoring institution, the Wisconsin Alumni Research Foundation (WARF; Madison, WI).
In November 2007, two independent reports announced the generation of induced pluripotent stem (iPS) cells by reprogramming adult human dermal fibroblasts with defined transcription factors and without using embryos or eggs 2, 3 . The senior author on one of the direct reprogramming papers was Thomson; the other was Kyoto University's Shinya Yamanaka (now at the San Francisco-based Gladstone Institute). In a separate December proceeding, the USPTO rejected an application that was a continuation of the '806 patent (known as '854) that sought to expand Thomson's claims to all pluripotent human stem cells, not just embryonic cells 4 . And the controversy has continued this year. On 25 February, a USPTO ruling withdrew all rejections of the '913 patent presented in the previous nonfinal USPTO action, effectively allowing the patent's composition of matter claims. Two weeks later, the agency upheld and affirmed the claims of the '780 and '806 patents.
In this article, we describe the rationale behind recent USPTO decisions and examine the impact of iPS cell discoveries on the current stem cell patent landscape. We contend that the rejection of claims that attempt to catch all pluripotent cells may provide openings to invent beyond the original discoveries. The rulings suggest that characteristics of cells such as gene signatures may be of primary importance to claim new pluripotent lines. We believe these events may signal new rules of engagement in the battle for dominance in stem cell IP. Although the '913 patent does not contain process claims, the examiner concluded that for the artisan to jump directly from rodents to primates and humans without first mastering the isolation and maintenance of higher mammals underscores the lack of predictability in the art of isolating and maintaining ES cells at the time of Thomson's invention. Without predictability, there is no reasonable expectation of success and thus no prima facie case of obviousness 8 .
Current status of the WARF patents
The most recent office decisions for the '780 and '806 process patent claims followed suit. The USPTO withdrew the rejection of claims to the isolation method described in '780 and '806, previously considered by the office to be the same as Williams's, saying Williams's methods "would not extend to the method of isolation of ES cells from other mammals" 9 . The agency also withdrew the initial obviousness rejection of the method claims, reasoning that three prior art references demonstrate that the technique used to isolate mouse ES cells was unpredictable and not universally applicable to the isolation of ES cells from other species, particularly human [10] [11] [12] . This stands in contrast to the USPTO's earlier reasoning in which it maintained that Williams's patent disclosure illustrates the goal of most animal studies as a penultimate step to deriving hES cells with therapeutic possibilities: the patent provides the motivation for eventually isolating hES cells. In light of the patents and publications discussed above, the USPTO had initially ruled that the discoveries were obvious to a person having ordinary skill in the art and endeavoring to extend the method of isolating ES cells from one mammalian species (mice, pigs or sheep) to another (humans).
The '854 continuation, which claims all pluripotent human stem cells, was rejected "because the specification, although being enabling for a preparation of pluripotent hES cells, does not reasonably provide enablement for a preparation of pluripotent hS [human stem] cells" 4 . Relying on extrinsic publications, the USPTO concluded that a type of pluripotent human stem cell produced from human primordial germ cells expresses SSEA-1, in contrast to hES cells produced from the inner cell mass of human blastocysts, which do not 13 . Thus, the lack of the SSEA-1 cell surface marker is a characteristic only of pluripotent hES cells, but not of other pluripotent kinds of human stem cells.
The USPTO decisions are final and cannot be appealed. In the United States, reexaminations are not uncommon and don't always reflect a weakness in the patent. In fact, the patent holders themselves may request reexaminations for the express purpose of strengthening their claims. And most reexaminations, although they may take years to resolve, uphold the patent under challenge. During the reexamination period, the patents are presumed to be valid, and as such, WARF continued to demand licensing fees and negotiate royalty arrangements 14 . Furthermore, the reexamination may have favored WARF, in part because during the challenge time the patents remained fully in force, and because it could increase its IP estate by filing follow-on inventions that further define the field. Most importantly, now that the three original patents have been upheld, the end result is that WARF may emerge in a stronger position because of the challenges 15 . The situation is different for the continuation, which remains rejected.
It should be noted that a reexamination cannot raise any new question of patentability 16 . Therefore, consideration of any new scientific discoveries such as iPS cells, or discussion of scientific and economic concerns raised by the consumer-rights organizations (for example, harm to hES cell research from restrictive licensing policies or diversion of taxpayer dollars meant for research to pay for licensing fees), is outside the scope of reexamination and had no bearing on the final decision for Thomson's existing patents 17 .
Are iPS cells entrapped by WARF patents?
Human iPS cells were shown to be similar to hES cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes and telomerase activity. Moreover, in general, except for a few cells at the edge of the colonies, human iPS cells did not express SSEA-1 (ref.
2).
Whether Thomson's patents would cover human iPS cells depends primarily on the definition of the term 'pluripotent hES cells' . The claims of the original patents do not define the term; therefore, the courts would have to rely on other sources 18 . According to the US National Institutes of Health (NIH; Bethesda, MD), "an ES cell is defined by its origin. It is derived from the blastocyst stage of the embryo" (http://stemcells.nih.gov/info/ scireport/chapter2.asp). The USPTO, on the other hand, in its final action rejecting '854, relied on the structural definition of the term 'embryonic' , as discussed above. The rejection may be significant for the WARF patent estate, as Thomson's most recent iPS paper contains the following statement: "The human iPS cells described here meet the defining criteria we originally proposed for human ES cells, with the significant exception that the iPS cells are not derived from embryos" 3 . If the term 'human ES cells' covered only pluripotent human stem cells derived from embryos, the patent would not cover iPS cells. Conversely, if the term covered every pluripotent human stem cell that did not express SSEA-1, the Thomson patent would cover iPS cells. Thus, the continuation-had it been granted-sought to cover the new iPS cell lines. Furthermore, the presence or absence of SSEA-1 markers on the cell type being considered for patenting may be a primary factor in determining infringement of Thomson's existing patents.
With the validity and scope of Thomson's patents now resolved, the USPTO rulings on stem cell patents will presumably affect future patent applications in the field. Most notably, Yamanaka has filed an international patent application, entitled "Nuclear reprogramming factor," under the World Intellectual Property Organization (WIPO; Geneva) Patent Cooperation Treaty where he claims "a means for inducing the reprogramming of a differentiated cell without using any embryo or ES cell and establish[ing] an inducible pluripotent stem cell having similar pluripotency and growing ability to those of an ES cell in a simple manner and with good reproductivity" 19 . Yamanaka's group used genes that were shown to play pivotal roles in the maintenance of ES cell identity and selected 24 as candidates for transcription factors that induce pluripotency in somatic cells.
Yamanaka's patent application claims priority of his earlier filing of December 2005, in advance of his August 2006 report describing work in which four genes directly reprogrammed mouse fibroblasts to embryonic-like states 20 . Yamanaka's international application lists the United States among designated countries. However, as the application was filed in Japanese, rather than English, it does not bar later US applications from being granted a patent 21 . Therefore, assuming that Thomson subsequently filed an application claiming human iPS cells, he could be entitled to a patent, providing that the USPTO considered his invention nonobvious in light of Yamanaka's August paper.
Recent USPTO decisions suggest that a patent applicant can rebut challenges of anticipating 
Conclusions
Given recent rulings by the USPTO, future stem cell patent applications will presumably be narrower, claiming physical but not functional (such as cell potency) characteristics. The scope of a specific stem cell patent could arguably be described by claiming unique cellsurface markers, gene expression patterns or other molecular and genetic characteristics that distinguish them from lines described in the public domain.
If the makeup of these iPS lines-whether reprogrammed directly by genes or by exogenous factors revealed through future experiments-is indeed nonobvious and useful, it nevertheless remains to be seen whether patents on iPS cells will become a central piece of stem cell IP. However, with the recent rejection of the '854 continuation and the decisions to uphold '780, '806 and '913, the iPS discoveries may represent the first pluripotent cell inventions described outside the foundational hES cell patents. In the short run, these cells may be especially important for deriving disease-specific lines for basic research and drug discovery.
As the debate over hES cell research continues, new questions may emerge over prior art and over which iPS claim, Yamanaka or Thomson, takes priority. These questions and others may usher in a new battle over discoveries using direct reprogramming, born from the crucible of the ES cell controversy.
